Kura Oncology (KURA) Competitors

Kura Oncology (NASDAQ:KURA) and Biohaven (NYSE:BHVN) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, community ranking, earnings and risk.

Do insiders & institutionals have more ownership in KURA or BHVN?

88.8% of Biohaven shares are owned by institutional investors. 5.5% of Kura Oncology shares are owned by insiders. Comparatively, 16.0% of Biohaven shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Do analysts rate KURA or BHVN?

Kura Oncology currently has a consensus target price of $25.50, indicating a potential upside of 332.20%. Biohaven has a consensus target price of $62.77, indicating a potential upside of 207.60%. Given Kura Oncology's higher possible upside, analysts plainly believe Kura Oncology is more favorable than Biohaven.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kura Oncology	0 Sell rating(s)	3 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	2.92
Biohaven	0 Sell rating(s)	0 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	3.07

Which has higher valuation and earnings, KURA or BHVN?

Kura Oncology has higher revenue and earnings than Biohaven. Kura Oncology is trading at a lower price-to-earnings ratio than Biohaven, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Kura Oncology	$53.88M	8.84	-$152.63M	-$2.03	-2.91
Biohaven	N/A	N/A	-$408.17M	-$9.39	-2.17

Does the media refer more to KURA or BHVN?

In the previous week, Biohaven had 14 more articles in the media than Kura Oncology. MarketBeat recorded 15 mentions for Biohaven and 1 mentions for Kura Oncology. Kura Oncology's average media sentiment score of 1.01 beat Biohaven's score of 0.70 indicating that Kura Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Kura Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biohaven	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer KURA or BHVN?

Kura Oncology received 30 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 69.65% of users gave Kura Oncology an outperform vote while only 67.33% of users gave Biohaven an outperform vote.

Company	Underperform	Outperform
Kura Oncology	Outperform Votes 436 69.65%	Underperform Votes 190 30.35%
Biohaven	Outperform Votes 406 67.33%	Underperform Votes 197 32.67%

Is KURA or BHVN more profitable?

Kura Oncology's return on equity of -44.09% beat Biohaven's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Kura Oncology	N/A	-44.09%	-39.57%
Biohaven	N/A	-225.12%	-158.89%

Which has more volatility and risk, KURA or BHVN?

Kura Oncology has a beta of 0.83, suggesting that its stock price is 17% less volatile than the S&P 500. Comparatively, Biohaven has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Summary

Kura Oncology beats Biohaven on 10 of the 17 factors compared between the two stocks.